| Name | L-Lysinamide, N-acetyl-L-norleucyl-L-α-aspartyl-β-alanyl-3-(2-naphthalenyl)-D-alanyl-L-arginyl-L-tryptophyl-, (2→7)-lactam |
|---|---|
| Synonyms |
(3S,6S,9R,16S,24S)-3-((1H-Indol-3-yl)methyl)-16-((S)-2-acetamidohexanamido)-6-(3-guanidinopropyl)-9-(naphthalen-2-ylmethyl)-2,5,8,11,15,18-hexaoxo-1,4,7,10,14,19-hexaazacyclotetracosane-24-cboxamide
L-Lysinamide, N-acetyl-L-norleucyl-L-α-asptyl-β-alanyl-3-(2-naphthalenyl)-D-alanyl-L-ginyl-L-tryptophyl-, (2→7)-lactam MMPIP hydrochloride |
| Description | PG106 is a potent and selective human melanocortin 3 (hMC3) receptor antagonist (IC50=210 nM) and has noactivity at hMC4 receptors (EC50=9900 nM) and hMC5 receptor[1]. |
|---|---|
| Related Catalog | |
| Target |
IC50: 210 nM (hMC3 receptor) EC50: 9900 nM (hMC4 receptor)[1] |
| References |
| Density | 1.40±0.1 g/cm3 (20 °C, 760 mmHg) |
|---|---|
| Molecular Formula | C51H69N13O9 |
| Molecular Weight | 1008.18000 |
| Exact Mass | 1007.53000 |
| PSA | 353.58000 |
| LogP | 4.81610 |